Korro Bio (KRRO) Operating Leases (2020 - 2026)

Korro Bio's Operating Leases history runs 7 years deep, the most recent figure standing at $42.9 million for Q1 2026.

• Quarterly Operating Leases changed 0.01% year-over-year to $42.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.9 million (changed 0.01% YoY) and the FY2025 annual result came in at $40.8 million, down 6.13% from the prior year.
• Operating Leases was $42.9 million for Q1 2026 at Korro Bio, up from $40.8 million in the prior quarter.
• Across five years, Operating Leases topped out at $44.6 million in Q2 2025 and bottomed at $209000.0 in Q4 2022.
• A 5-year average of $33.6 million and a median of $36.3 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases plunged 99.28% — and 2023, when it soared 14835.89%.
• Korro Bio's Operating Leases stood at $209000.0 in 2022, then surged by 14835.89% to $31.2 million in 2023, then jumped by 39.29% to $43.5 million in 2024, then fell by 6.13% to $40.8 million in 2025, then gained by 5.07% to $42.9 million in 2026.
• Business Quant data shows KRRO's Operating Leases at $42.9 million in Q1 2026, $40.8 million in Q4 2025, and $41.5 million in Q3 2025.